Glioblastoma in tunisia: a retrospective study about 41 cases.
##plugins.themes.academic_pro.article.main##
Abstract
SUMMARY
Background: Glioblastoma (GB) is the most common and lethal primary brain tumor in adults representing 25% of primary brain tumors in adults. The objective of our study was to report the epidemiologic, clinical and therapeutic features of GB in Tunisia.
Methods: Our retrospective study included 41 patients with histologically confirmed GB treated between 2006 and 2012 at the medical oncology departments of Abderrahmane Mami hospital in Ariana and the military hospital in Tunis.
Results: Median age was 54 years (13 to 72 years) and sex-ratio was 2.3. Karnofsky performance status (KPS) was <70% in 31.7% of cases, while Recursive partitioning analysis radiation therapy oncology group (RTOG-RPA) classification was III in 11 (26.8%), IV in 19 (46.3%), V in 10 (24.3%) and VI in 1 (2.4%) cases. Complete resection (CR) was achieved in 29 patients (70.7%), partial resection (PR) or tumor debulking in 5 patients (12.2%) and biopsy alone (BA) in 7 patients (17.1%). All patients received brain radiotherapy (RT) at a dose of 60 Gy combined with concurrent temozolomide (TMZ). Nineteen patients (46.3%) received adjuvant TMZ, 8 of them completed 6 cycles. Median overall survival (OS) was 12 months (2 to 56 months). Six, 12, 18 and 24-months OS rates were 84.6%, 57.6%, 35.4% and 20.7%, OS being correlated to age, KPS, RPA and quality of resection.
Conclusion: Our retrospective study is the first African GB series. Despite it included predominantly poor prognosis patients with impaired neurocognitive function and adjuvant treatment discontinuation, our median OS was comparable to Stupp.
Background: Glioblastoma (GB) is the most common and lethal primary brain tumor in adults representing 25% of primary brain tumors in adults. The objective of our study was to report the epidemiologic, clinical and therapeutic features of GB in Tunisia.
Methods: Our retrospective study included 41 patients with histologically confirmed GB treated between 2006 and 2012 at the medical oncology departments of Abderrahmane Mami hospital in Ariana and the military hospital in Tunis.
Results: Median age was 54 years (13 to 72 years) and sex-ratio was 2.3. Karnofsky performance status (KPS) was <70% in 31.7% of cases, while Recursive partitioning analysis radiation therapy oncology group (RTOG-RPA) classification was III in 11 (26.8%), IV in 19 (46.3%), V in 10 (24.3%) and VI in 1 (2.4%) cases. Complete resection (CR) was achieved in 29 patients (70.7%), partial resection (PR) or tumor debulking in 5 patients (12.2%) and biopsy alone (BA) in 7 patients (17.1%). All patients received brain radiotherapy (RT) at a dose of 60 Gy combined with concurrent temozolomide (TMZ). Nineteen patients (46.3%) received adjuvant TMZ, 8 of them completed 6 cycles. Median overall survival (OS) was 12 months (2 to 56 months). Six, 12, 18 and 24-months OS rates were 84.6%, 57.6%, 35.4% and 20.7%, OS being correlated to age, KPS, RPA and quality of resection.
Conclusion: Our retrospective study is the first African GB series. Despite it included predominantly poor prognosis patients with impaired neurocognitive function and adjuvant treatment discontinuation, our median OS was comparable to Stupp.
Keywords:
Glioblastoma, surgery, temozolomide, radiotherapy, survival.##plugins.themes.academic_pro.article.details##
References
- Ahmadloo N, Kani AA, Mohammadianpanah M et al. Treatment outcome and prognostic factors of adult glioblastoma multiforme. J Egypt Natl Canc Inst 2013; 25: 21-30.
- Stark AM, Van de Bergh J, Hedderich J, Mehdorn HM, Arya Nabavi A. Glioblastoma: Clinical characteristics, prognostic factors and survival in 492 patients. Clin Neurol Neurosurg 2012; 114:840-5.
- Baldi I, Huchet A, Bauchet L, Loiseau H. Epidemiology of glioblastoma. Neurosurg 2010; 56:433-40.
- Chargari C, Feuvret L, Bauduceau O et al. Treatment of elderly patients with glioblastoma: From clinical evidence to molecular highlights. Cancer Treat Rev 2012; 38: 988-95.
- Mirimanoff RO, Gorlia T, Mason W et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006; 24:2563-9.
- Paquis P, Menei P. Conclusions: Glioblastomas. Standards, options, recommendations. Neurosurg 2010;56: 503-7.
- Stupp R, Mason WP, Van den Bent MJ et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 2005; 352: 987-96.
- Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28: 1963-72.
- Chinota O, Soulierc P, Frenay M. Chemotherapy and targeted treatments in glioblastomas. Neurosurg 2010;56:491-8.
- Lonjon M, Mondot L, Lonjon N, Chanalet S. Clinical factors in glioblastoma and neuroradiology. Neurosurg 2010;56 : 449-54.
- Chaichana KL, Martinez-Gutierrez JC, De la Garza-Ramos R et al. Factors associated with survival for patients with glioblastoma with poor pre-operative functional status. Journal of Clinical Neuroscience 2013; 20 : 818-23.
- Stummer W, Reulen HJ, Meinel T et al. Identification of and adjustment for bias. Neurosurg 2008;62 :564-76.
- Eljamel MS, Goodman C, Mosely H. ALA and Photofrin fluorescenceguided resection and repetitive PDT in glioblastoma multiform: a single centre Phase III randomized controlled trial. Lasers Med Sci 2008;23:361-7.
- Fontaine D, Paquis P. Glioblastoma: Clinical, radiological and biological prognostic factors. Neurosurgery 2010;56: 467-76.
- Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-9.